Bausch Health Companies Inc. (BHC)
BHCNYSEBiotechnology: Pharmaceutical Preparations
$8.29
-0.1100 (-1.31%) today
At the close, Nov 10, 4:00 PM ET. After hours $8.29 +0.06%
- Market cap
- $3.10bn
- P/E
- 1.7
- EPS, last 4 quarters
- $4.89
- Dividend yield
- –
- Day range
- $8.15 to $8.37
- 52-week range
- $4.33 to $9.04
- Average volume
- 4.44m
- Previous close
- $8.40
Analysts
3 coveringHold0 buy, 3 hold, 0 sell
Targets a year out average $8.33, +0.5% from here
Earnings
next estimate $1.19Next report
Dec 2025
-10.7%
Mar 2026
-3.7%
Jun 2026
+31.3%
Sep 2026
+63.9%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $2.80bn | $2.52bn | $2.85bn | $2.94bn |
| Gross profit | $2.00bn | $1.79bn | $2.08bn | $2.21bn |
| Operating income | $474.00m | -$950.00m | $740.00m | $983.00m |
| Net income | -$112.00m | -$1.42bn | $258.00m | $436.00m |
Last four quarters: revenue $11.11bn, margin -7.6%, free cash flow $1.86bn
News
8 latest- BHC Q3 Earnings Call Highlights Raised Outlook, Xifaxan RisksZacks · 6 days ago
- Is Bausch Health (BHC) Stock Outpacing Its Medical Peers This Year?Zacks · Nov 3, 2026
- Bausch Health Companies Consensus Price Target Increased by 11.58% to $7.29Fintel · Nov 2, 2026
- Healthcare Stocks Rise: GKOS Surges 33%, TDOC Gains 30%, BHC Advances 26%, MESO Jumps Over 16% RTTNews · Oct 29, 2026
- BHC Q3 Earnings Beat on Salix Growth, Stock Gains 9% as Outlook RisesZacks · Oct 29, 2026
- Bausch Health (BHC) Q3 2026 Earnings Call TranscriptThe Motley Fool · Oct 29, 2026
- Bausch Health Companies Inc. Reports Third Quarter 2026 Consolidated Revenues of $2.94 billionFintel · Oct 28, 2026
- What Bausch Health Cos (BHC) Said on Its Q3 Earnings CallMarketBeat · Oct 28, 2026
The company
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- Region
- North America
- Website
- bauschhealth.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.